Earnings Scheduled For May 1, 2025
Exact Sciences Q1 2025 Earnings Preview
Craig-Hallum Maintains Exact Sciences(EXAS.US) With Buy Rating
Exact Sciences Appoints Leslie Trigg to Board
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Phathom Pharmaceuticals (PHAT) and Exact Sciences (EXAS)
Exact Sciences to Present Cologuard Test Adherence and Predicted Preference Data at Digestive Disease Week 2025
Goldman Sachs: The Q1 performance of U.S. pharmaceutical stocks is reassuring, and the Industry sentiment is slightly becoming more positive.
Goldman Sachs stated that amid cautious sentiment from investors towards the USA pharmaceutical sector before the Earnings Reports season, the performance of USA pharmaceutical companies that have reported results so far for the first quarter has not been worse than expected, and in some cases, it has even exceeded expectations.
Exact Sciences, CAVA, Lockheed, Intuit, Coinbase: Trending by Analysts
Earnings Preview: EXAS to Report Financial Results Post-market on May 01
This Exact Sciences Insider Increased Their Holding In The Last Year
Exact Sciences' Stock Resilience and Legal Outlook Drive Buy Rating
Exact Sciences Launches the Oncodetect MRD Test
Exact Sciences Launch of Oncodetect A New Test Designed To Detect Molecular Residual Disease (MRD) Across Multiple Solid Tumors
Exact Sciences Launches the Oncodetect Molecular Residual Disease Test
TD Cowen Maintains Exact Sciences(EXAS.US) With Buy Rating, Cuts Target Price to $75
Express News | Exact Sciences Corp : TD Cowen Cuts Target Price to $75 From $86
Bernstein Reaffirms Their Buy Rating on Exact Sciences (EXAS)
Here's Why Exact Sciences (NASDAQ:EXAS) Can Afford Some Debt
Exact Sciences' Oncotype DX Test Gets New Backing in JAMA Oncology, Offers Reliable Insights for Diverse Breast Cancer Patients
JAMA Oncology Publication Strengthens Evidence for Oncotype DX Test Reliability Across Racial and Ethnic Groups